This is a first in France: a brand new 3D skin scanner system has taken place within the Marseille Public Assistance. Installed at the automated melanoma screening center at the Hôpital de la Conception (5e), this machine manufactured by the American company Canfield Scientific makes it possible to acquire high-precision images of the entire skin surface.
The time of a flash, the 92 cameras of the Vectra 3D make it possible to acquire the image of a digital avatar in three dimensions of the patient. A “screening” which makes it possible to list all the nevus of the body in barely a second. A significant progress for the dermatologist, for whom the detection of suspicious lesions can take a long time in certain patients who present numerous moles. ” As part of the regular monitoring of high-risk patients, this is a phenomenal time saver “, underlines Prof. Jean-Jacques Grob. Precious medical time at a time when the dermatological offer is shrinking. ” This will make it possible to follow more patients and refer those who need it the most to the dermatologist. »
Although it is already inspecting its first patients, the Vectra 3D is nevertheless still in the experimental phase. A research project carried out in collaboration with Luminy’s LIS (Computer and Systems Laboratory) ultimately aims to develop an innovative system for the automatic detection of suspicious melanoma lesions using artificial intelligence (AI). ” These algorithms will allow us to detect lesions in the same individual at an early stage, before the melanoma metastasizes. This is an important issue for reducing mortality », stresses Dr. Jilliana Monnier, in charge of the study.
As with many aggressive cancers, the prognosis of melanoma indeed depends on early screening. Between 82 to 99% of cases observe a 5-year survival rate, while it drops to 30 to 50% when the melanoma progresses to the metastatic stage. Despite its rarity, this disease caused mainly by exposure to UV rays remains a major public health problem: the increase in its incidence rate in France ” is higher than that of any other cancer, despite prevention policies “, notes the AP-HM.